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INTRODUCTION
Pulmonary fibrosis is a condition caused by 
various pulmonary disorders and often culminates 
in death.1 The development of fibrosis occurs 
mainly in response to tissue damage caused by an 
injury, through several phases i.e the coagulation, 
the inflammatory, the fibroblast proliferation/
migration and the final remodeling phase. The 
damaged epithelial cells, during the inflammatory 
phase, produce inflammatory mediators, 
causing migration of the immune cells from the 
circulation both in and around the damaged lung 
tissue. The immune-activated cells then produce 
proinflammatory and anti-inflammatory cytokines 
which further initiate fibroblast recruitment and 
proliferation, as well as the conversion of alveolar 
epithelial cells into mesenchymal cells that 
resemble the fibroblast cells.2 The differentiation 
of fibroblasts into myofibroblasts stimulates the 
secretion of extracellular matrix components, 
causing accumulation of extracellular matrix at 
the site of the damaged tissue, leading to gradual 
thickening and rigidification of lung tissue 
rendering it unable to function properly.3
Transforming Growth Factor-β (TGF-β) is a 
cytokine produced by alveolar macrophages. 
TGF-β plays a pivotal role in the differentiation of 
fibroblasts into myofibroblasts, which in turn express 
α-smooth muscle actin (α-SMA) and produce 
excessive extracellular matrix.4-6 Another cytokine, 
Interleukin (IL)-4, is responsible to stimulate the 
proliferation of fibroblasts and initiate myofibroblast 
differentiation.7 IL-4 is able to induce the production 
of TGF-β from lung fibroblasts, thereby increasing 
the production of extracellular matrix.8,9 Interferon 
(IFN)-γ, a proinflammatory and profibrotic cytokine 
produced by the immune cells during inflammation, 
decreases the fibroblast procollagen mRNA levels, 
thereby inhibiting fibroblast proliferation as well as 
collagen production.10,11
The damage caused by fibrosis is unrepairable. 
However, appropriate treatment may be able to 
improve the quality of life of the patient. Goat milk 
kefir is a dairy product produced by fermentation of 
goat milk with the help of kefir “grains” containing of 
a mixture of lactic acid bacteria, yeasts, and fungi. 12 
Kefir has been proven to exhibit immunomodulatory 
activity in several diseases, through the stimulation 
of cytokine production by the immune cells. A 
study demonstrated that kefir decreased the TGF-β 
expression in HT-29 cell culture.13 Another study 
indicated that the administration of kefir increased 
IFN-γ expression in the mice infected with G. 
intestinalis.14 The expressions of the mRNAs of 
IL-4 genes were downregulated following the 
administration of kefir in murine breast cancer 
cells.15 The objective of the present study was to 
observe the potency of goat milk kefir in regulating 
the concentrations of plasma TGF-β1, IL-4, and 
IFN-γ, as well as α-SMA expression, in the rat model 
with bleomycin-induced pulmonary fibrosis.
ABSTRACT
Objective: This study aimed to investigate the immunomodulatory capacity of goat kefir on 
pulmonary fibrosis rat model. Material and Methods: Twenty-five male rats were randomly 
divided into five groups: one group only received induction with bleomycin (0.3 mg/rat) to 
induce pulmonary fibrosis; three groups were treated with different doses (2.5, 3.5, and 4.5 
mL/200 g BW) of goat kefir, following the induction with bleomycin, for 30 days; and one group 
served as negative control, did not receive bleomycin induction as well as kefir. On day 30, all 
the animals were sacrificed. Plasma levels of  TGF-β, IL-4, and IFN-y were measured using the 
ELISA method, and the expression of α-SMA in myofibroblast cells was examined with the 
help of immunohistochemistry assay. Results: Induction with bleomycin significantly elevated 
the expressions of TGF-β, IL-4, and IFN-y in comparison to the control group. Following the 
administration of kefir (3.5 and 4.5 mL/200 g BW), the concentration of TGF-β was significantly 
decreased (p<0.05); whereas, the concentration of IFN-y increased slightly (p<0.05) only in the 
group that received the 4.5 mL/200 g BW dose of kefir. In contrast, IL-4 exhibited increasing 
levels with higher doses of kefir (p<0.05). The expression of α-SMA in myofibroblasts showed 
a tendency to decline following the administration of kefir, although this decline was not 
statistically significant. Conclusions: Goat kefir caused a reduction in the TGF-β levels in fibrosis 
conditions; however, the kefir elicited an immunosuppressive effect during the progression of 
the pulmonary fibrosis.
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MATERIAL AND METHODS
Material
Etawah goat milk kefir was purchased from Inti Jaya Makmur (PIA STPP 
Malang, Indonesia). Kefir was obtained immediately after production, 
divided into aliquots, and rapidly frozen and stored at -80 °C until use.
Animals
The present study was approved by The Ethical Research Commission 
of the Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia 
(Approval number: 39/EC/KEPK/01/2017). Twelve to sixteen-week-
old Wistar male rats (n = 25), weighing 150-200 g each, were obtained 
from the animal house of the Faculty of Science and Technology, State 
Islamic University Maulana Malik Ibrahim. The rats were randomly 
divided into five groups: group one received only bleomycin, group 
two to four were induced with bleomycin (2 mg/kg BW.), followed by 
administration of kefir at different doses (2.5, 3.5, and 4.5 mL/200 g BW, 
respectively for each group), and group five did not receive bleomycin 
as well as kefir, served as negative control. All the rats were housed in 
plastic cages on hardwood shavings, kept at an ambient temperature 
of 24 ±2 °C under a 12-h normal phase light-dark cycle, and were fed 
on BR1 Comfeed pellets (PT. Charoen Pokphand, Indonesia). Drinking 
water and food were freely available to all the rats. Acclimatization to 
the aforementioned conditions was performed at least one week prior 
to the induction with bleomycin.
Establishment of bleomycin-induced pulmonary fibrosis 
in rats and the kefir treatment
Rats were anesthetized with 0.05 mL of ketamine (Ketamine 10% inj 
KEPRO B.V., Holland), followed by 0.05 mL xylazine (Xyla, Interchemie, 
Holland), through intramuscular injection. Bleomycin solution was 
prepared by mixing Bleomycin hydrochloride (Bleocin, Nippon 
Kayaku, Kalbe Farma, Indonesia) and saline (0.9%), divided into 
aliquots and then stored at 4 °C. The rats were induced with Bleomycin 
(a dose of 0.3mg in 100 µL, 50 µL per nostril) using a micropipette. 
The animals were allowed to recover immediately afterward. This 
procedure was performed nine times consecutively, once each day. A 
similar administration protocol has also been reported previously in 
order to induce substantial and sustained pulmonary fibrosis in mice.16 
Kefir was administered, using oral gavages, for 30 days following the 
first day of bleomycin induction.
On Day 30, all the rats were sacrificed using cervical dislocation. The 
chest cavity was opened up by performing the dissection. A blood 
sample was collected from the heart, preferably from the ventricle; 
the process was performed gradually in order to avoid heart collapse. 
The collected blood sample was immediately placed into a vacutainer 
tube containing EDTA. Blood plasma was obtained by centrifugation 
(15 min at 3000 rpm), apportioned into 0.5-mL aliquots, and stored at 
-20 °C for use in the ELISA experiments. Following the removal of the 
heart, the lung was reserved for the histopathological examination and 
the immunohistochemistry assays.
ELISA
Plasma samples were assayed for the measurement of TGF-β1, IL-4, 
and IFN-γ, using solid-phase ELISA kits (Rat TGF-β1 ELISA Kit Cat. 
No. ER1378 and Rat IL-4 ELISA Kit Cat. No. ER0041, China) and 
Elabscience kit (Rat IFN-γ ELISA Kit Cat. No. E-EL-R0009, China), 
following manufacturers’ guidelines. The ELISA kits were purchased 
from FineTest. The outcomes were measured using an iMark™ 
Microplate Absorbance Reader (Bio-Rad).
Immunohistochemistry assay
The lung samples were immersed in 10% neutral buffered formalin for 
24 h. Following the fixation, lungs were trimmed, and three transverse 
sections that were each approximately 0.3 cm in thickness were excised 
through the lung sample (superior, median, and caudal parts) in order 
to include the main bronchi as well as the pulmonary alveoli. The 
sections were then dehydrated using an increasing- concentration 
graded series of ethyl alcohol, followed by embedding in one block of 
paraffin wax. Three serial histological slices (4 pm) were obtained from 
each section, which were then processed for the immunohistochemical 
analysis. Alfa-smooth muscle actin polyclonal antibody (FineTest, Cat. 
No. ENT5053, China) was used in the immunohistochemical analysis. 
Alpha smooth muscle actin-stained slides were examined under a light 
microscope (Olympus BX51) connected to a color photomicrography 
digital camera system (DP70) and a PC HP Z600 Workstation.
Using 40x objective lens and the digital camera, the fields with all visible 
air-ways were selected and displayed on a monitor. The image analysis 
software (OlyVIA) program was used to measure the area of all stained 
tissue, and then divide it by the constant field of interest area, thereby 
calculating a bronchiole wall-area fraction value for 12 fields, which 
was the average for each bronchiole. Data were presented as averages.
Statistical analyses
All the results were expressed as mean±sem. Statistical analyses were 
performed using SPSS 21.0 software. Parametric one-way ANOVA and 
Least Significant Difference (LSD) test were performed for TGF-β1 and 
IFN-γ endpoint readouts, while non-parametric Kruskal-Wallis test 
and Mann-Whitney U test were performed for the IL-4 and α-SMA 
endpoint readouts. The differences were considered significant at P 
<0.05.
RESULTS
Effect of kefir on the plasma levels of TGF-β1, IL-4, and 
IFN-γ
Measurement of blood plasma TGF-β1 revealed that the levels of 
TGF-β1 were elevated in the bleomycin-induced group (16.55±0.76 
ng/mL), and were significantly higher in comparison to the healthy 
group (10.28±1.36 ng/mL). Following the administration of kefir 
at a dose of 2.5 mL/200 g BW, the levels of TGF-β1 reduced slightly 
(though not statistically significant). However, a significantly decreased 
concentration of TGF-β1 was shown in the groups that received kefir at 
doses of 3.5 mL/200 g BW and 4.5 mL/200 g BW (Figure 1A).
The concentration of IL-4 in blood plasma was dramatically higher in 
the bleomycin-induced group (164.16 ± 1.93 pg/mL), in comparison to 
the healthy rats (22.29 ± 1.06 pg/mL), which was further increased with 
the administration of higher doses of kefir (538.68 ± 6.45 pg/mL for 
kefir dose 3.5 mL/200 g BW and 571.08 ± 1.14 pg/mL for kefir dose 4.5 
mL/200 g BW) (Figure 1B).
In contrast, the induction with bleomycin reduced the concentration 
of IFN-γ from 0.102 ± 0.001 pg/mL (in the healthy rat group) to 0.099 
± 0.002 pg/mL (in the bleomycin-induced group). The administration 
of kefir could recover the IFN-γ levels in the blood plasma only slightly 
(0.103 ± 0.001 pg/mL) in the group treated with kefir at dose of 4.5 
mL/200 g BW (Figure 1C).
Effect of kefir on the expression of α-smooth muscle 
actin (SMA) in myofibroblasts
Induction with bleomycin evidently widened the area over which the 
myofibroblasts expressed alpha-smooth muscle actin (α-SMA) (7.08 
± 1.09 µm), compared to the area observed for the healthy group 
(3.18 ± 0.29 µm). Administration of kefir at a dose of 2.5 mL/200 g 
BW narrowed the area of α -SMA expression in myofibroblasts (5.79 
± 0.39 pm). However, higher doses of kefir (4.5 mL/200 g BW) could 
not further narrowed the area of α-SMA expression (4.88 ± 0.35 pm) to 
reach a level similar to that in the healthy rats (Figure 2).
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Figure 1: Effect of the administration of different dosis of kefir: 2.5 mL, 3.5 mL and 4.5 mL/200 g BW on the plasma level of 
TGF-β1 (A), IL-4 (B), IFN-γ (C) in bleomycin-induced rat. Values are expressed as mean ± SEM, n=5. *and ** indicated p<0.05 
and p<0.01 respectively.
Figure 2: Effects of goat kefir on the expression of alpha-smooth muscle actin (α-SMA) in myofibroblast of lung tissue of 
pulmonary fibrosis animal model. Values expressed as mean ±SEM, n=5. * and ** indicated p<0.05 and p<0.01 respectively. 
Histology of α-smooth muscle actin expression in bronchioles wall of a rat model of ubchronic pulmonary fibrosis: control group 
(A). bleomycin group (B). bleomycin + kefir 2.5 mL/200 g BW (C). bleomycin + kefir 3.5 mL/200 g BW (D). bleomycin + kefir 4.5 
mL/200 g BW (E). Alpha-SMA expression in bronchioles wall (black arrows), blood vessels (red arrowhead), Bar: 200 μm.
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DISCUSSION
Intranasal administration of bleomycin, an alternative experimental 
model to study lung fibrosis in a rat model, is a method that does 
not cause injuries to the trachea. Bleomycin is known to stimulate 
inflammatory responses in the lung tissues, with increased infiltration 
of leukocytes following the stimulation of inflammatory cells, 
proliferation of fibroblasts, and the activation of myofibroblasts which 
secrete ECM components into the alveolar interstitial space, gradually 
resulting in pulmonary fibrosis.17
In the present study, the effect of kefir on the regulatory signals 
(TGF-β1, IFN-γ, and IL-4) in blood plasma, as well as on the expression 
of α-SMA in myofibroblasts, was investigated in the bleomycin-induced 
pulmonary fibrosis rat model. It was observed that the expression of 
TGF-β1 was 1.6-fold higher in the bleomycin-induced group compared 
to the healthy group, which declined with the administration of different 
doses of kefir and reached a value similar to that in the healthy un-
induced group. There is compelling evidence from both experimental 
and clinical studies for an increased TGF-β1 expression in response 
to bleomycin induction. Du et al. reported that the elevated levels of 
TGF-β and IL-4 observed in the lung tissue with fibrosis were lower 
for the control group compared to those in the group of Balb/c mice 
induced with bleomycin.18 It was observed in the present study that 
the levels of TGF-β1 significantly declined following the exposure to 
goat kefir. TGF-β serves as a mediator in regulating cell proliferation 
and differentiation, as well as in the synthesis of several components 
of extracellular matrix. Elevated production of TGF-β1 has been 
linked with the repair system in the fibrotic processes in several organs 
including lungs. Downregulation of lung TGF-β1 mRNA expression 
in the bleomycin-induced pulmonary fibrosis in rodent has been 
demonstrated to be correlated with decreased extracellular matrix 
production in the lung, thereby ameliorating the progression of fibrosis. 
The decline in the TGF-β levels has been associated with the regulation 
of NF-kB, which involves the production of IL-1.19 K. marxianus (one 
of the yeast species present in kefir) was able to downregulate the NF-
kB pathway in the intestinal epithelial cells in vitro, thereby decreasing 
the expression of TGF-β1.20
Surprisingly, the concentration of IL-4 in the blood plasma post the 
bleomycin induction showed further increase post kefir administration. 
The high expression of IL-4 in the bleomycin-induced fibrosis model 
has been demonstrated to be caused mainly by macrophages and T 
lymphocytes.9 Since IL-4 belongs to the group of proinflammatory 
cytokines, the elevated concentration of IL-4 leads to the progression of 
fibrosis. In contrast, the research conducted by Lee et al. demonstrated 
a decrease in the IL-4 concentration in the bronchoalveolar lavage in 
ovalbumin-sensitized Balb/c mice.21 IL-4 apparently also represses the 
synthesis of IFN-γ. In the present study, the plasma levels of IFN-γ 
observed in the healthy rats were very low. The slight increase in IFN-γ 
levels post administration of kefir could have been due to the repression 
effect caused by the high expression of IL-4. This result was in contrast 
to the result obtained in the study conducted by Vinderola et al., who 
demonstrated that the administration of kefir in healthy mice increased 
the IL-4, IL-2, and IFN-γ expressions in the lamina propria of the 
intestinal organ.22 This discrepancy could be a result of the difference 
in the background experimental settings between the in vitro and in 
vivo experiments.
Venderola performed her experiment using the peripheral blood 
mononuclear cells (PBMCs) obtained from normal humans treated 
with kefir. She suggested that increasing IFN-γ production in the 
peritoneal macrophage cells (in vitro) could be is stimulated by the 
presence of sphingomyelin phospholipids present as a constituent in 
kefir.23 Sphingomyelin is a sphingolipid present in the cell membranes 
of animals and bacteria, which play an important role in cell structure 
and function. Sphingomyelin is also responsible in several signaling 
pathways. Sphingomyelin metabolism generates products, one of which 
is the IFN-γ cytokine, that perform important functions in the cell.24 
IL-4 and IFN-γ act in an antagonistic manner by suppressing each 
other's synthesis, while they are also able to induce the expression of 
each other. In a study involving mice infected with Candida albicans, 
IL-4 induced IFN-γ production from T cells.25 Induction of IL-4 by 
IFN-γ is mediated by STAT proteins (STAT4 and STAT6).26 IL-4 in 
synergistic association with IL-2 initiates the production of IFN-γ, 
which is dependent on STAT6.27 In mouse colitis models, exposure to 
IL-4 enhanced the IFN-y expression.28
Differentiation of fibroblasts into myofibroblasts during the 
fibroproliferative phase is very important for fibrosis formation, and is 
influenced by TGF-β1. TGF-β1 mediates the fibroblast differentiation 
through the phosphorylation of Smad2 and Smad3 signal transducer 
proteins, resulting in the formation of their complexes with Smad4 and 
then translocation into the cell nucleus. This Smad protein complex 
increases the myofibroblast target gene regulation.29 Myofibroblasts are 
the fibroblast phenotypes that actively synthesize extracellular matrix 
proteins (metalloproteinases and type I collagen). Myofibroblasts 
exhibit high α-SMA expression. 30,31 Observations in skin cell cultures 
that were exposed with TGF-β1 revealed α-smooth muscle actin 
expression, unlike the control. In the present study, increasing the 
goat milk kefir doses was followed by a slight decrease in the α-SMA 
expression, although the decrease was not statistically significant. 
This suggested that increasing the doses of goat milk kefir up to 4.5 
mL/200 g BW was able to decrease the concentration of TGF-β1 in the 
blood plasma, although it was not sufficient to lessen the expression of 
α-SMA in the bronchioles, therefore, not being sufficient to inhibit the 
progression of fibrosis due to bleomycin induction.
The findings of the present study propose an important implication for 
fibrosis therapy, suggesting that during the treatment of fibrosis, the 
patient should not consume goat milk kefir as it may worsen the fibrosis 
progression.
CONCLUSIONS
The data presented clearly demonstrated that goat kefir decreased 
the concentration of TGF-β1, significantly increased the IL-4 levels, 
and only slightly raised the levels of IFN-γ in bleomycin- induced 
sub chronic pulmonary fibrosis rat model. Nevertheless, since the 
expression of α-SMA in the bronchioles is still high, therefore fail to 
inhibit to the progression of fibrosis.
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